AR113486A1 - Análogos de incretina y sus usos - Google Patents
Análogos de incretina y sus usosInfo
- Publication number
- AR113486A1 AR113486A1 ARP180103560A ARP180103560A AR113486A1 AR 113486 A1 AR113486 A1 AR 113486A1 AR P180103560 A ARP180103560 A AR P180103560A AR P180103560 A ARP180103560 A AR P180103560A AR 113486 A1 AR113486 A1 AR 113486A1
- Authority
- AR
- Argentina
- Prior art keywords
- incretine
- analogues
- activity
- receptors
- incretin analogs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Se proporcionan análogos de incretina que tienen actividad en cada uno de los receptores de GIP, GLP-1 y glucagón. Los análogos de incretina tienen características estructurales que dan como resultado una actividad equilibrada y una duración de acción extendida en cada uno de estos receptores. También se proporcionan métodos para tratar enfermedades tales como diabetes mellitus, dislipidemia, hepatopatía grasa, síndrome metabólico, esteatohepatitis no alcohólica y obesidad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762608613P | 2017-12-21 | 2017-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR113486A1 true AR113486A1 (es) | 2020-05-06 |
Family
ID=65003519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180103560A AR113486A1 (es) | 2017-12-21 | 2018-12-05 | Análogos de incretina y sus usos |
Country Status (24)
Country | Link |
---|---|
US (2) | US11542313B2 (es) |
EP (1) | EP3727426A1 (es) |
JP (2) | JP6961838B2 (es) |
KR (2) | KR102444783B1 (es) |
CN (1) | CN111491658B (es) |
AR (1) | AR113486A1 (es) |
AU (1) | AU2018388962B2 (es) |
BR (1) | BR112020010244A2 (es) |
CA (1) | CA3084005C (es) |
CL (1) | CL2020001635A1 (es) |
CO (1) | CO2020006255A2 (es) |
CR (1) | CR20200255A (es) |
DO (1) | DOP2020000123A (es) |
EA (1) | EA202091290A1 (es) |
EC (1) | ECSP20032650A (es) |
IL (1) | IL275468A (es) |
JO (1) | JOP20200137A1 (es) |
MA (1) | MA51288A (es) |
MX (1) | MX2020006548A (es) |
PE (1) | PE20210162A1 (es) |
PH (1) | PH12020551025A1 (es) |
SG (1) | SG11202005606VA (es) |
TW (2) | TWI744579B (es) |
WO (1) | WO2019125938A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
WO2021034815A1 (en) | 2019-08-19 | 2021-02-25 | Eli Lilly And Company | Methods of making incretin analogs |
TWI795698B (zh) * | 2019-12-18 | 2023-03-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
JP2023550594A (ja) | 2020-10-30 | 2023-12-04 | ノヴォ ノルディスク アー/エス | Glp-1、gip、およびグルカゴン受容体三重作動薬 |
CN114685642B (zh) * | 2020-12-29 | 2024-03-29 | 浙江和泽医药科技股份有限公司 | 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途 |
MX2023008330A (es) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |
AR125086A1 (es) | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
AU2022280225A1 (en) * | 2021-05-26 | 2024-01-04 | The United Bio-Technology (Hengqin) Co., Ltd. | Multi-agonist and use thereof |
CN115572326A (zh) * | 2021-06-21 | 2023-01-06 | 广东东阳光药业有限公司 | Glp-1、gcg和gip受体的三重激动剂 |
EP4358994A1 (en) | 2021-06-23 | 2024-05-01 | Eli Lilly and Company | An incretin analog for use in glycemic control and weight management |
TWI828434B (zh) * | 2021-11-19 | 2024-01-01 | 大陸商南京明德新藥研發有限公司 | 釘合肽及其應用 |
WO2023088140A1 (zh) * | 2021-11-19 | 2023-05-25 | 南京明德新药研发有限公司 | 订合肽及其应用 |
CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
CN114957387B (zh) * | 2022-05-18 | 2023-06-20 | 华南理工大学 | 一种具有降血糖作用的巴旦木多肽及其制备方法与应用 |
WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
WO2024067662A1 (zh) * | 2022-09-28 | 2024-04-04 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
WO2024077149A2 (en) | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2650038T3 (es) * | 2008-06-17 | 2018-01-16 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
BRPI1013588A2 (pt) | 2009-03-27 | 2016-04-19 | Glaxo Group Ltd | composição |
MX342409B (es) * | 2010-01-20 | 2016-09-28 | Zealand Pharma As | Tratamiento de enfermedades cardiacas. |
AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
EP2707713A2 (en) * | 2011-05-10 | 2014-03-19 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
US10093713B2 (en) * | 2013-11-06 | 2018-10-09 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
CA2929107C (en) * | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
AR104932A1 (es) * | 2015-06-22 | 2017-08-23 | Lilly Co Eli | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) |
TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
JP6712323B2 (ja) | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、glp−1及びgip受容体のすべてに活性を有する三重活性体 |
EP3217027A1 (de) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Breites einlageelement zum einfassen einer ankerstange |
TWI744579B (zh) * | 2017-12-21 | 2021-11-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
TWI810937B (zh) * | 2017-12-21 | 2023-08-01 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
-
2018
- 2018-12-05 TW TW107143624A patent/TWI744579B/zh active
- 2018-12-05 TW TW110136047A patent/TWI809515B/zh active
- 2018-12-05 AR ARP180103560A patent/AR113486A1/es unknown
- 2018-12-14 SG SG11202005606VA patent/SG11202005606VA/en unknown
- 2018-12-14 WO PCT/US2018/065663 patent/WO2019125938A1/en unknown
- 2018-12-14 EP EP18830618.7A patent/EP3727426A1/en active Pending
- 2018-12-14 AU AU2018388962A patent/AU2018388962B2/en active Active
- 2018-12-14 CR CR20200255A patent/CR20200255A/es unknown
- 2018-12-14 EA EA202091290A patent/EA202091290A1/ru unknown
- 2018-12-14 MA MA051288A patent/MA51288A/fr unknown
- 2018-12-14 CA CA3084005A patent/CA3084005C/en active Active
- 2018-12-14 JP JP2020551786A patent/JP6961838B2/ja active Active
- 2018-12-14 CN CN201880081212.3A patent/CN111491658B/zh active Active
- 2018-12-14 JO JOP/2020/0137A patent/JOP20200137A1/ar unknown
- 2018-12-14 KR KR1020207017387A patent/KR102444783B1/ko active IP Right Grant
- 2018-12-14 KR KR1020227031761A patent/KR102622642B1/ko active IP Right Grant
- 2018-12-14 PE PE2020000802A patent/PE20210162A1/es unknown
- 2018-12-14 BR BR112020010244-0A patent/BR112020010244A2/pt unknown
- 2018-12-14 US US16/768,960 patent/US11542313B2/en active Active
- 2018-12-14 MX MX2020006548A patent/MX2020006548A/es unknown
-
2020
- 2020-05-22 CO CONC2020/0006255A patent/CO2020006255A2/es unknown
- 2020-06-17 IL IL275468A patent/IL275468A/en unknown
- 2020-06-17 DO DO2020000123A patent/DOP2020000123A/es unknown
- 2020-06-17 CL CL2020001635A patent/CL2020001635A1/es unknown
- 2020-06-17 PH PH12020551025A patent/PH12020551025A1/en unknown
- 2020-06-19 EC ECSENADI202032650A patent/ECSP20032650A/es unknown
-
2021
- 2021-10-13 JP JP2021168050A patent/JP2022033724A/ja active Pending
-
2022
- 2022-11-21 US US18/057,398 patent/US20230203121A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20032650A (es) | Análogos de incretina y sus usos | |
ECSP20032306A (es) | Análogos de incretina y sus usos | |
CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
IL268702B (en) | Use of a long-acting dual glp-1/glucagon receptor agonist for the treatment of non-alcoholic fatty liver disease | |
CL2018001522A1 (es) | Focalización de péptidos para dirigir virus adenoasociados (aavs) | |
DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CO2017000510A2 (es) | Constructos de car | |
AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
CR20150664A (es) | Moduladores de los receptores de estrógeno y sus usos | |
DOP2022000122A (es) | Analogos de incretina y sus usos | |
AR101592A1 (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cd123 | |
AR112904A1 (es) | Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas |